TiGenix: Transparency Information
July 02 2018 - 4:01PM
PRESS RELEASEREGULATED
INFORMATION
Transparency Information
Leuven (Belgium) - July 2, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG)
publishes information in accordance with articles 15 and 18 of the
Belgian Law of May 2, 2007 regarding the publication of
major holdings in issuers whose securities are admitted to trading
on a regulated market and including various provisions (the Law)
and the Royal Decree of February 14, 2008 regarding the
publication of major holdings.
Following the issuance of 11,905,171 new shares
on July 2, 2018 resulting from the exercise of 11,905,171 warrants
of TiGenix NV, the transparency data have changed as follows
(status on July 2, 2018):
· Information
to be published in accordance with Article 15, §1, al. 1 of the
Law
Total of the registered capital: |
EUR 30,882,907.70 |
Total
number of securities conferring voting rights: |
307,973,027 |
Total
number of voting rights (denominator): |
307,973,027 |
· Information
to be published in accordance with Article 15, §1, al. 2 of the
Law
Total number of rights (materialized or not in
financial instruments) to subscribe for yet unissued financial
instruments that are treated as securities conferring voting
rights: 585,443 granted and outstanding warrants which, in case
they are all exercised, give rise to a total number of 585,443
voting rights.
TiGenix NV has not issued any other rights to
subscribe to securities conferring voting rights or any securities
without voting rights.
· Information
to be published in accordance with Article 18, §1 of the
Law
Each physical or legal person acquiring or
transferring TiGenix NV's shares is required to notify the Belgian
Financial Services and Markets Authority (FSMA) and TiGenix NV each
time their shareholding crosses a threshold of three percent (3%)
of the total number of voting securities (the denominator) (upwards
or downwards). Such notification is also required when the
threshold of five percent (5%) or a multiple of five percent (5%)
is crossed.
Complete information regarding this requirement
can be found in Article 14 of the articles of association of
TiGenix NV.
Notifications must be submitted to both the FSMA
and TiGenix NV.
To the FSMA:
- by e-mail: trp.fin@fsma.be, and
- a signed copy (for reasons of legal certainty) by fax: +32 2
220 59 12
A copy of the notification must also be sent to TiGenix NV for
the attention of Claudia Jiménez, Senior Director Investor
Relations and Communications:
- by e-mail: investor@tigenix.com, and
- a signed copy (for reasons of legal certainty) by fax: +32 16
39 79 70
For submitting the notifications, the FSMA
recommends to use its standard form TR-1BE that is available on the
FSMA website (https://www.fsma.be/en/node/7121) or can be requested
by e-mail with TiGenix NV: investor@tigenix.com.
Detailed information regarding the transparency
legislation can be found on the website of the FSMA.
For more information
TiGenix Claudia Jiménez Senior Director Investor Relations and
Communications Tel: +34918049264 claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024